It is not about product being allowed to stay in the market, it is about foreign producers being allowed to stay on past November.
From an interview with the FDA commissioner 2 days ago:
CORLEY: Yeah. As you know, and as I think everybody knows these days, just a few companies do control the infant formula industry. And that plant in Michigan, as you mentioned, a huge part of why this crisis occurred. And you acknowledged early on that the concentration of the formula industry really deserved more scrutiny. So what is the FDA doing when it comes to diversifying the market? And, you know, will any change kind of be permanent to allow for more companies to make formula?
CALIFF: Well, I'd stress this is really administration-wide. I mean, everybody has pitched in to help out here, including the strategy going forward. And I'll point to three things quickly. The first, we are encouraging people to increase the different sites within the United States, more producing facilities. The second is with the foreign manufacturers that are now importing under our scrutiny with high-quality formula, we want to create a situation where they can stay on the market. You know, right now, we've expedited the paperwork, but they'll need to go through all the usual standards, just like a domestic producer will do. And the third component is we need to monitor the system more closely. And there's legislation in front of Congress that would help us be able to keep track of things better so that we can pre-empt these problems rather than waiting for them to happen.
A2M Price at posting:
$4.90 Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)